HONG KONG – China has again demonstrated efforts to improve its health care system by motivating drug innovation and strengthening regulation. This time it is being done through overhauling the country's drug administration law and introducing a similar law for vaccines. Read More
HONG KONG – To get new drugs to market faster, the South Korean government has plans that could see approval periods for biopharmaceuticals cut drastically, as part of its ongoing efforts to improve regulations and prompt greater investment in the biotechnology and health care industries, increasingly seen as a key pillar of economic growth. Read More
HONG KONG – Seeking to expand its presence in Europe, Shionogi & Co. Ltd. inked a contract with Italian firm Molteni Farmaceutici SpA to distribute Rizmoic (naldemedine), its treatment for opioid-induced constipation (OIC), in Italy and Poland, and plans to export two additional drugs, cefiderocol and lusutrombopag, to the European market. Read More
PERTH, Australia – Probably nobody was as surprised by the results of Australia's national election than re-elected Liberal Party Prime Minister Scott Morrison, but he has a lot to answer to when it comes to policy initiatives that affect the life sciences sector here. Read More
Barely a day goes by without news relating to cell and gene therapy companies being announced. Given the ongoing developments, it is not surprising that the sector continues to attract financing and business development remains robust, with biopharma companies ensuring that they secure a position in the space for themselves through partnering and acquisitions. Read More
A study led by Agency of Science, Technology and Research (A*STAR) Genome Institute of Singapore (GIS) scientists has shown that subpopulations of lung cancer cells have different metabolic dependencies. The insight highlights the need to understand cellular metabolism within the context of tumor heterogeneity and promoting development of targeted therapies. Read More
Immuron Ltd., of Melbourne, Australia, priced an underwritten public offering of 500,000 American depositary shares (ADSs), each representing 40 ordinary shares, at a price of $4 each. The company has also granted to the underwriter a 45-day option to acquire an additional 75,000 ADSs to cover overallotments. Read More
